Search

Your search keyword '"Dreger, Peter"' showing total 1,389 results
Start Over Author "Dreger, Peter" Search Limiters Full Text Search Limiters Peer Reviewed
1,389 results on '"Dreger, Peter"'

1. Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma

Author

Locke, Frederick L., Filosto, Simone, Chou, Justin, Vardhanabhuti, Saran, Perbost, Regis, Dreger, Peter, Hill, Brian T., Lee, Catherine, Zinzani, Pier L., Kröger, Nicolaus, López-Guillermo, Armando, Greinix, Hildegard, Zhang, Wangshu, Tiwari, Gayatri, Budka, Justin, Marincola, Francesco M., To, Christina, Mattie, Mike, Schupp, Marco, Cheng, Paul, Bot, Adrian, Shen, Rhine, Bedognetti, Davide, Miao, Harry, and Galon, Jérôme

Published
2024
Full Text
View/download PDF

4. Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial

Author

Schubert, Maria-Luisa, Schmitt, Anita, Hückelhoven-Krauss, Angela, Neuber, Brigitte, Kunz, Alexander, Waldhoff, Philip, Vonficht, Dominik, Yousefian, Schayan, Jopp-Saile, Lea, Wang, Lei, Korell, Felix, Keib, Anna, Michels, Birgit, Haas, Dominik, Sauer, Tim, Derigs, Patrick, Kulozik, Andreas, Kunz, Joachim, Pavel, Petra, Laier, Sascha, Wuchter, Patrick, Schmier, Johann, Bug, Gesine, Lang, Fabian, Gökbuget, Nicola, Casper, Jochen, Görner, Martin, Finke, Jürgen, Neubauer, Andreas, Ringhoffer, Mark, Wolleschak, Denise, Brüggemann, Monika, Haas, Simon, Ho, Anthony D., Müller-Tidow, Carsten, Dreger, Peter, and Schmitt, Michael

Published
2023
Full Text
View/download PDF

6. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy

Author

Stein-Thoeringer, Christoph K., Saini, Neeraj Y., Zamir, Eli, Blumenberg, Viktoria, Schubert, Maria-Luisa, Mor, Uria, Fante, Matthias A., Schmidt, Sabine, Hayase, Eiko, Hayase, Tomo, Rohrbach, Roman, Chang, Chia-Chi, McDaniel, Lauren, Flores, Ivonne, Gaiser, Rogier, Edinger, Matthias, Wolff, Daniel, Heidenreich, Martin, Strati, Paolo, Nair, Ranjit, Chihara, Dai, Fayad, Luis E., Ahmed, Sairah, Iyer, Swaminathan P., Steiner, Raphael E., Jain, Preetesh, Nastoupil, Loretta J., Westin, Jason, Arora, Reetakshi, Wang, Michael L., Turner, Joel, Menges, Meghan, Hidalgo-Vargas, Melanie, Reid, Kayla, Dreger, Peter, Schmitt, Anita, Müller-Tidow, Carsten, Locke, Frederick L., Davila, Marco L., Champlin, Richard E., Flowers, Christopher R., Shpall, Elizabeth J., Poeck, Hendrik, Neelapu, Sattva S., Schmitt, Michael, Subklewe, Marion, Jain, Michael D., Jenq, Robert R., and Elinav, Eran

Published
2023
Full Text
View/download PDF

7. Hematopoietic stem cell transplantation for DLBCL: a report from the European Society for Blood and Marrow Transplantation on more than 40,000 patients over 32 years

Author

Berning, Philipp, Fekom, Mathilde, Ngoya, Maud, Goldstone, Anthony H., Dreger, Peter, Montoto, Silvia, Finel, Hervé, Shumilov, Evgenii, Chevallier, Patrice, Blaise, Didier, Strüssmann, Tim, Carpenter, Ben, Forcade, Edouard, Castilla-Llorente, Cristina, Trneny, Marek, Ghesquieres, Hervé, Capria, Saveria, Thieblemont, Catherine, Blau, Igor Wolfgang, Meijer, Ellen, Broers, Annoek E. C., Huynh, Anne, Caillot, Denis, Rösler, Wolf, Nguyen Quoc, Stephanie, Bittenbring, Jörg, Nagler, Arnon, Galimard, Jacques-Emmanuel, Glass, Bertram, Sureda, Anna, and Schmitz, Norbert

Published
2024
Full Text
View/download PDF

8. Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients

Author

Schmälter, Ann-Kristin, Ngoya, Maud, Galimard, Jacques-Emmanuel, Bazarbachi, Ali, Finke, Jürgen, Kröger, Nicolaus, Bornhäuser, Martin, Stelljes, Matthias, Stölzel, Friedrich, Tischer, Johanna, Schroeder, Thomas, Dreger, Peter, Blau, Igor-Wolfgang, Savani, Bipin, Giebel, Sebastian, Esteve, Jordi, Nagler, Arnon, Schmid, Christoph, Ciceri, Fabio, and Mohty, Mohamad

Published
2024
Full Text
View/download PDF

9. PTCy versus ATG as graft-versus-host disease prophylaxis in mismatched unrelated stem cell transplantation

Author

Penack, Olaf, Abouqateb, Mouad, Peczynski, Christophe, Boreland, William, Gülbas, Zafer, Gedde-Dahl, Tobias, Castilla-Llorente, Cristina, Kröger, Nicolaus, Eder, Mathias, Rambaldi, Alessandro, Bonifazi, Francesca, Blau, Igor Wolfgang, Stelljes, Matthias, Dreger, Peter, Moiseev, Ivan, Schoemans, Hélène, Koenecke, Christian, and Peric, Zinaida

Published
2024
Full Text
View/download PDF

13. Chronic Lymphocytic Leukaemia

Author

Tournilhac, Olivier, Dreger, Peter, Kröger, Nicolaus, editor, Gribben, John, editor, Chabannon, Christian, editor, Yakoub-Agha, Ibrahim, editor, and Einsele, Hermann, editor

Published
2022
Full Text
View/download PDF

14. Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma

Author

Elsawy, Mahmoud, Chavez, Julio C., Avivi, Irit, Larouche, Jean-François, Wannesson, Luciano, Cwynarski, Kate, Osman, Keren, Davison, Kelly, Rudzki, Jakob D., Dahiya, Saurabh, Dorritie, Kathleen, Jaglowski, Samantha, Radford, John, Morschhauser, Franck, Cunningham, David, Martin Garcia-Sancho, Alejandro, Tzachanis, Dimitrios, Ulrickson, Matthew L., Karmali, Reem, Kekre, Natasha, Thieblemont, Catherine, Enblad, Gunilla, Dreger, Peter, Malladi, Ram, Joshi, Namita, Wang, Wei-Jhih, Solem, Caitlyn T., Snider, Julia Thornton, Cheng, Paul, To, Christina, and Kersten, Marie José

Published
2022
Full Text
View/download PDF

15. Donor KIR genotype based outcome prediction after allogeneic stem cell transplantation: no land in sight

Author

Schetelig, Johannes, primary, Baldauf, Henning, additional, Heidenreich, Falk, additional, Hoogenboom, Jorinde D., additional, Spellman, Stephen R., additional, Kulagin, Alexander, additional, Schroeder, Thomas, additional, Sengeloev, Henrik, additional, Dreger, Peter, additional, Forcade, Edouard, additional, Vydra, Jan, additional, Wagner-Drouet, Eva Maria, additional, Choi, Goda, additional, Paneesha, Shankara, additional, Miranda, Nuno A. A., additional, Tanase, Alina, additional, de Wreede, Liesbeth C., additional, Lange, Vinzenz, additional, Schmidt, Alexander H., additional, Sauter, Jürgen, additional, Fein, Joshua A., additional, Bolon, Yung-Tsi, additional, He, Meilun, additional, Marsh, Steven G. E., additional, Gadalla, Shahinaz M., additional, Paczesny, Sophie, additional, Ruggeri, Annalisa, additional, Chabannon, Christian, additional, and Fleischhauer, Katharina, additional

Published
2024
Full Text
View/download PDF

16. Impact of comorbidities and body mass index on the outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of EBMT

Author

Polverelli, Nicola, primary, Bonneville, Edouard F., additional, de Wreede, Liesbeth C., additional, Koster, Linda, additional, Kröger, Nicolaus Martin, additional, Schroeder, Thomas, additional, Peffault de Latour, Régis, additional, Passweg, Jakob, additional, Sockel, Katja, additional, Broers, Annoek E. C., additional, Clark, Andrew, additional, Dreger, Peter, additional, Blaise, Didier, additional, Yakoub‐Agha, Ibrahim, additional, Petersen, Soeren Lykke, additional, Finke, Jürgen, additional, Chevallier, Patrice, additional, Helbig, Grzegorz, additional, Rabitsch, Werner, additional, Sammassimo, Simona, additional, Arcaini, Luca, additional, Russo, Domenico, additional, Drozd‐Sokolowska, Joanna, additional, Raj, Kavita, additional, Robin, Marie, additional, Battipaglia, Giorgia, additional, Czerw, Tomasz, additional, Hernández‐Boluda, Juan Carlos, additional, and McLornan, Donal P., additional

Published
2024
Full Text
View/download PDF

18. Proteogenomics refines the molecular classification of chronic lymphocytic leukemia

Author

Herbst, Sophie A., Vesterlund, Mattias, Helmboldt, Alexander J., Jafari, Rozbeh, Siavelis, Ioannis, Stahl, Matthias, Schitter, Eva C., Liebers, Nora, Brinkmann, Berit J., Czernilofsky, Felix, Roider, Tobias, Bruch, Peter-Martin, Iskar, Murat, Kittai, Adam, Huang, Ying, Lu, Junyan, Richter, Sarah, Mermelekas, Georgios, Umer, Husen Muhammad, Knoll, Mareike, Kolb, Carolin, Lenze, Angela, Cao, Xiaofang, Österholm, Cecilia, Wahnschaffe, Linus, Herling, Carmen, Scheinost, Sebastian, Ganzinger, Matthias, Mansouri, Larry, Kriegsmann, Katharina, Kriegsmann, Mark, Anders, Simon, Zapatka, Marc, Del Poeta, Giovanni, Zucchetto, Antonella, Bomben, Riccardo, Gattei, Valter, Dreger, Peter, Woyach, Jennifer, Herling, Marco, Müller-Tidow, Carsten, Rosenquist, Richard, Stilgenbauer, Stephan, Zenz, Thorsten, Huber, Wolfgang, Tausch, Eugen, Lehtiö, Janne, and Dietrich, Sascha

Published
2022
Full Text
View/download PDF

19. PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL.

Author

Dreger, Peter, Sureda, Anna, Ahn, Kwang, Eapen, Mary, Litovich, Carlos, Finel, Herve, Boumendil, Ariane, Gopal, Ajay, Herrera, Alex, Schmid, Christoph, Diez-Martin, José, Fuchs, Ephraim, Bolaños-Meade, Javier, Gooptu, Mahasweta, Al Malki, Monzr, Castagna, Luca, Ciurea, Stefan, Dominietto, Alida, Blaise, Didier, Ciceri, Fabio, Tischer, Johanna, Corradini, Paolo, Montoto, Silvia, Robinson, Stephen, Gülbas, Zafer, and Hamadani, Mehdi

Subjects
Adult, Aged, Female, Hematopoietic Stem Cell Transplantation, Humans, Lymphoma, Large B-Cell, Diffuse, Male, Middle Aged, Retrospective Studies, Tissue Donors, Transplantation Conditioning, Young Adult
Abstract

This study retrospectively compared long-term outcomes of nonmyeloablative/reduced intensity conditioning (NMC/RIC) allogeneic hematopoietic cell transplantation (allo-HCT) from a haploidentical family donor (haplo-HCT) using posttransplant cyclophosphamide (PTCy) with those of matched sibling donor (MSD) and matched unrelated donor (MUD) with or without T-cell depletion (TCD+/TCD-) in patients with relapsed diffuse large B-cell lymphoma (DLBCL). Adult patients with DLBCL who had undergone their first NMC/RIC allo-HCT between 2008 and 2015 were included. Recipients of haplo-HCT were limited to those receiving graft-versus-host disease (GVHD) prophylaxis with PTCy. GVHD prophylaxis in MSD was limited to calcineurin inhibitor (CNI)-based approaches without in vivo TCD, while MUD recipients received CNI-based prophylaxis with or without TCD. Outcome analyses for overall survival (OS) and progression-free survival (PFS), nonrelapse mortality (NRM), and disease relapse/progression were calculated. A total of 1438 patients (haplo, 132; MSD, 525; MUD TCD+, 403; and MUD TCD-, 378) were included. Patients with haplo donors were significantly older, had a better performance status and had more frequently received total body irradiation-based conditioning regimens and bone marrow grafts than MSD and MUD TCD+ or TCD-. 3-year OS, PFS, NRM and relapse/progression incidence after haplo-HCT was 46%, 38%, 22%, and 41%, respectively, and not significantly different from outcomes of matched donor transplants on multivariate analyses. Haplo-HCT was associated with a lower cumulative incidence of chronic GVHD compared with MSD, MUD TCD+/TCD-. NMC/RIC haplo-HCT with PTCy seems to be a valuable alternative for patients with DLBCL considered for allo-HCT but lacking a matched donor.

Published
2019

20. Outcomes of Haploidentical Transplantation in Patients with Relapsed Multiple Myeloma: An EBMT/CIBMTR Report

Author

Sahebi, Firoozeh, Garderet, Laurent, Kanate, Abraham S, Eikema, Diderik-Jan, Knelange, Nina Simone, Alvelo, Omar F Dávila, Koc, Yener, Blaise, Didier, Bashir, Qaiser, Moraleda, José M, Dreger, Peter, Sanchez, James F, Ciurea, Stefan, Schouten, Harry, Shah, Nirav N, Verbeek, Mareike, Rösler, Wolf, Diez-Martin, Jose L, Schoenland, Stefan, D'Souza, Anita, Kröger, Nicolaus, and Hari, Parameswaran

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Regenerative Medicine, Stem Cell Research, Clinical Trials and Supportive Activities, Transplantation, Clinical Research, Hematology, Rare Diseases, Cancer, Good Health and Well Being, Adult, Aged, Allografts, Disease-Free Survival, Female, Follow-Up Studies, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Incidence, Male, Middle Aged, Multiple Myeloma, Recurrence, Retrospective Studies, Risk Factors, Survival Rate, Allogeneic hematopoietic cell transplantation, Haploidentical, Multiple myeloma, Clinical Sciences, Immunology, Cardiovascular medicine and haematology
Abstract

Allogeneic hematopoietic cell transplantation (allo-HCT) using siblings and matched donors has the potential for long-term disease control in a subset of high-risk patients with multiple myeloma (MM); however, the data on using haploidentical donors in this disease are limited. We conducted a retrospective analysis to examine the outcomes of patients with MM who underwent haploidentical allo-HCT within European Society for Blood and Marrow Transplantation/Center for International Blood and Marrow Transplant Research centers. A total of 96 patients underwent haploidentical allo-HCT between 2008 and 2016. With a median follow-up of 24.0 months (range, 13.2 to 24.9 months), 97% (95% confidence interval [CI], 93% to 100%) of patients had neutrophil engraftment by day 28, and 75% (95% CI, 66% to 84%) achieved platelet recovery by day 60. Two-year progression-free survival (PFS) was 17% (95% CI, 8% to 26%), and overall survival (OS) was 48% (95% CI, 36% to 59%). At 2 years, the cumulative risk of relapse/progression was 56% (95% CI, 45% to 67%), and 1-year nonrelapse mortality (NRM) was 21% (95% CI, 13% to 29%). The incidences of acute graft-versus-host-disease (GVHD) grades II-IV by 100 days and chronic GVHD at 2 years were 39% (95% CI, 28% to 49%) and 46% (95% CI, 34% to 59%), respectively. On univariate analysis, use of post-transplantation cyclophosphamide (PT-Cy) (54% [95% CI, 41% to 68%] versus 25% [95% CI, 1% to 48%]; P =.009) and use of bone marrow as source of stem cells (72% [95% CI, 55% to 89%] versus 31% [95% CI, 17% to 46%]; P = .001) were associated with improved OS at 2 years. Disease status, patient sex, intensity of conditioning regimen, recipient/donor sex mismatch, and cytomegalovirus serostatus had no impact on OS, PFS, or NRM. Haploidentical transplantation is feasible for patients with multiply relapsed or high-risk MM, with an encouraging 2-year OS of 48% and an NRM of 21% at 1 year, supporting further investigation of haploidentical allo-HCT in suitable candidates with MM.

Published
2019

21. GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany

Author

Bethge, Wolfgang A., Martus, Peter, Schmitt, Michael, Holtick, Udo, Subklewe, Marion, von Tresckow, Bastian, Ayuk, Francis, Wagner-Drouet, Eva Marie, Wulf, Gerald G., Marks, Reinhard, Penack, Olaf, Schnetzke, Ulf, Koenecke, Christian, von Bonin, Malte, Stelljes, Matthias, Glass, Bertram, Baldus, Claudia D., Vucinic, Vladan, Mougiakakos, Dimitrios, Topp, Max, Fante, Matthias A., Schroers, Roland, Bayir, Lale, Borchmann, Peter, Buecklein, Veit, Hasenkamp, Justin, Hanoun, Christine, Thomas, Simone, Beelen, Dietrich W., Lengerke, Claudia, Kroeger, Nicolaus, and Dreger, Peter

Published
2022
Full Text
View/download PDF

22. Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia

Author

Huber, Henriette, Edenhofer, Simone, von Tresckow, Julia, Robrecht, Sandra, Zhang, Can, Tausch, Eugen, Schneider, Christof, Bloehdorn, Johannes, Fürstenau, Moritz, Dreger, Peter, Ritgen, Matthias, Illmer, Thomas, Illert, Anna L., Dürig, Jan, Böttcher, Sebastian, Niemann, Carsten U., Kneba, Michael, Fink, Anna-Maria, Fischer, Kirsten, Döhner, Hartmut, Hallek, Michael, Eichhorst, Barbara, and Stilgenbauer, Stephan

Published
2022
Full Text
View/download PDF

23. Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics

Author

Hamadani, Mehdi, Ngoya, Maud, Sureda, Anna, Bashir, Qaiser, Litovich, Carlos Alejandro, Finel, Hervé, Chen, Yue, Boumendil, Ariane, Zain, Jasmine, Castagna, Luca, Cashen, Amanda F., Blaise, Didier, Shadman, Mazyar, Pastano, Rocco, Khimani, Farhad, Arat, Mutlu, Dietrich, Sascha, Schmitz, Norbert, Glass, Bertram, Kharfan-Dabaja, Mohamed A., Corradini, Paolo, Sauter, Craig S., Montoto, Silvia, Kwon, Mi, Herrera, Alex F., and Dreger, Peter

Published
2022
Full Text
View/download PDF

25. Endothelial Activation and Stress Index (EASIX) to predict mortality after allogeneic stem cell transplantation: a prospective study

Author

Penack, Olaf, primary, Luft, Thomas, additional, Peczynski, Christophe, additional, Benner, Axel, additional, Sica, Simona, additional, Arat, Mutlu, additional, Itäla-Remes, Maija, additional, Corral, Lucia López, additional, Schaap, Nicolaas P M, additional, Karas, Michal, additional, Raida, Ludek, additional, Schroeder, Thomas, additional, Dreger, Peter, additional, Metafuni, Elisabetta, additional, Ozcelik, Tulay, additional, Sandmaier, Brenda M, additional, Kordelas, Lambros, additional, Moiseev, Ivan, additional, Schoemans, Hélène, additional, Koenecke, Christian, additional, Basak, Grzegorz W, additional, and Peric, Zinaida, additional

Published
2024
Full Text
View/download PDF

28. American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma

Author

Munshi, Pashna N., Hamadani, Mehdi, Kumar, Ambuj, Dreger, Peter, Friedberg, Jonathan W., Dreyling, Martin, Kahl, Brad, Jerkeman, Mats, Kharfan-Dabaja, Mohamed A., Locke, Frederick L., Shadman, Mazyar, Hill, Brian T., Ahmed, Sairah, Herrera, Alex F., Sauter, Craig S., Bachanova, Veronika, Ghosh, Nilanjan, Lunning, Matthew, Kenkre, Vaishalee P., Aljurf, Mahmoud, Wang, Michael, Maddocks, Kami J., Leonard, John P., Kamdar, Manali, Phillips, Tycel, Cashen, Amanda F., Inwards, David J., Sureda, Anna, Cohen, Jonathon B., Smith, Sonali M., Carlo-Stella, Carmello, Savani, Bipin, Robinson, Stephen P., and Fenske, Timothy S.

Published
2021
Full Text
View/download PDF

29. Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas

Author

Liebers, Nora, Duell, Johannes, Fitzgerald, Donnacha, Kerkhoff, Andrea, Noerenberg, Daniel, Kaebisch, Eva, Acker, Fabian, Fuhrmann, Stephan, Leng, Corinna, Welslau, Manfred, Chemnitz, Jens, Middeke, Jan-Moritz, Weber, Thomas, Holtick, Udo, Trappe, Ralf, Pfannes, Roald, Liersch, Ruediger, Spoer, Christian, Fuxius, Stefan, Gebauer, Niklas, Caillé, Léandra, Geer, Thomas, Koenecke, Christian, Keller, Ulrich, Claus, Rainer, Mougiakakos, Dimitrios, Mayer, Stephanie, Huettmann, Andreas, Pott, Christiane, Trummer, Arne, Wulf, Gerald, Brunnberg, Uta, Bullinger, Lars, Hess, Georg, Mueller-Tidow, Carsten, Glass, Bertram, Lenz, Georg, Dreger, Peter, and Dietrich, Sascha

Published
2021
Full Text
View/download PDF

30. Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation

Author

Kharfan-Dabaja, Mohamed A, Kumar, Ambuj, Hamadani, Mehdi, Stilgenbauer, Stephan, Ghia, Paolo, Anasetti, Claudio, Dreger, Peter, Montserrat, Emili, Perales, Miguel-Angel, Alyea, Edwin P, Awan, Farrukh T, Ayala, Ernesto, Barrientos, Jacqueline C, Brown, Jennifer R, Castro, Januario E, Furman, Richard R, Gribben, John, Hill, Brian T, Mohty, Mohamad, Moreno, Carol, O'Brien, Susan, Pavletic, Steven Z, Pinilla-Ibarz, Javier, Reddy, Nishitha M, Sorror, Mohamed, Bredeson, Christopher, Carpenter, Paul, and Savani, Bipin N

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Cancer, Transplantation, Hematology, Rare Diseases, Clinical Research, Clinical Trials and Supportive Activities, Lymphoma, Antineoplastic Agents, Child, Child, Preschool, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Practice Guidelines as Topic, Salvage Therapy, Transplantation Conditioning, Transplantation, Homologous, Chronic lymphocytic leukemia, Allogeneic hematopoietic cell transplantation, BCR inhibitors, BCL-2 inhibitors, Clinical Sciences, Immunology, Cardiovascular medicine and haematology
Abstract

We sought to establish clinical practice recommendations to redefine the role of allogeneic hematopoietic cell transplantation (allo-HCT) for patients with chronic lymphocytic leukemia (CLL) in an era of highly active targeted therapies. We performed a systematic review to identify prospective randomized controlled trials comparing allo-HCT against novel therapies for treatment of CLL at various disease stages. In the absence of such data, we invited physicians with expertise in allo-HCT and/or CLL to participate in developing these recommendations. We followed the Grading of Recommendations Assessment, Development and Evaluation methodology. For standard-risk CLL we recommend allo-HCT in the absence of response or if there is evidence of disease progression after B cell receptor (BCR) inhibitors. For high-risk CLL an allo-HCT is recommended after failing 2 lines of therapy and showing an objective response to BCR inhibitors or to a clinical trial. It is also recommended for patients who fail to show an objective response or progress after BCR inhibitors and receive BCL-2 inhibitors, regardless of whether an objective response is achieved. For Richter transformation, we recommend allo-HCT upon demonstration of an objective response to anthracycline-based chemotherapy. A reduced-intensity conditioning regimen is recommended whenever indicated. These recommendations highlight the rapidly changing treatment landscape of CLL. Newer therapies have disrupted prior paradigms, and allo-HCT is now relegated to later stages of relapsed or refractory CLL.

Published
2016

31. CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparison

Author

Dreger, Peter, Dietrich, Sascha, Schubert, Maria-Luisa, Selberg, Lorenz, Bondong, Andrea, Wegner, Mandy, Stadtherr, Peter, Kimmich, Christoph, Kosely, Florentina, Schmitt, Anita, Pavel, Petra, Liebers, Nora, Luft, Thomas, Hegenbart, Ute, Radujkovic, Aleksandar, Ho, Anthony Dick, Müller-Tidow, Carsten, and Schmitt, Michael

Published
2020
Full Text
View/download PDF

33. Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents

Author

Roeker, Lindsey E., Dreger, Peter, Brown, Jennifer R., Lahoud, Oscar B., Eyre, Toby A., Brander, Danielle M., Skarbnik, Alan, Coombs, Catherine C., Kim, Haesook T., Davids, Matthew, Manchini, Steven T., George, Gemlyn, Shah, Nirav, Voorhees, Timothy J., Orchard, Kim H., Walter, Harriet S., Arumainathan, Arvind K., Sitlinger, Andrea, Park, Jae H., Geyer, Mark B., Zelenetz, Andrew D., Sauter, Craig S., Giralt, Sergio A., Perales, Miguel-Angel, and Mato, Anthony R.

Published
2020
Full Text
View/download PDF

36. Haematopoietic stem cell transplantation in adult soft-tissue sarcoma: an analysis from the European Society for Blood and Marrow Transplantation

Author

Heilig, Christoph E., Badoglio, Manuela, Labopin, Myriam, Fröhling, Stefan, Secondino, Simona, Heinz, Jürgen, Nicolas-Virelizier, Emmanuelle, Blaise, Didier, Korenbaum, Clément, Santoro, Armando, Verbeek, Mareike, Krüger, William, Siena, Salvatore, Passweg, Jakob R., Di Nicola, Massimo, Rifón, Jose, Dreger, Peter, Koehl, Ulrike, Chabannon, Christian, and Pedrazzoli, Paolo

Published
2020
Full Text
View/download PDF

37. Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry study

Author

Schubert, Maria-Luisa, primary, Bethge, Wolfgang A., additional, Ayuk, Francis A., additional, von Bonin, Malte, additional, Vucinic, Vladan, additional, Wagner-Drouet, Eva Marie, additional, Subklewe, Marion, additional, Baldus, Claudia D., additional, Glass, Bertram, additional, Marks, Reinhard, additional, Mougiakakos, Dimitrios, additional, Schroers, Roland, additional, Stelljes, Matthias, additional, Topp, Max S., additional, Wulf, Gerald, additional, Kröger, Nicolaus, additional, and Dreger, Peter, additional

Published
2023
Full Text
View/download PDF

38. Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party

Author

Penack, Olaf, primary, Peczynski, Christophe, additional, Koenecke, Christian, additional, Polge, Emmanuelle, additional, Sanderson, Robin, additional, Yakoub-Agha, Ibrahim, additional, Fegueux, Nathalie, additional, Daskalakis, Michael, additional, Collin, Matthew, additional, Dreger, Peter, additional, Kröger, Nicolaus, additional, Schanz, Urs, additional, Bloor, Adrian, additional, Ganser, Arnold, additional, Besley, Caroline, additional, Wulf, Gerald G., additional, Novak, Urban, additional, Moiseev, Ivan, additional, Schoemans, Hélène, additional, Basak, Grzegorz W., additional, Chabannon, Christian, additional, Sureda, Anna, additional, Glass, Bertram, additional, and Peric, Zinaida, additional

Published
2023
Full Text
View/download PDF

40. Allogeneic hematopoietic stem cell transplantation in patients aged 60-79 years in Germany (1998-2018): a registry study

Author

Weller, Jan Frederic, primary, Lengerke, Claudia, additional, Finke, Jürgen, additional, Schetelig, Johannes, additional, Platzbecker, Uwe, additional, Einsele, Hermann, additional, Schroeder, Thomas, additional, Faul, Christoph, additional, Stelljes, Matthias, additional, Dreger, Peter, additional, Blau, Igor W., additional, Wulf, Gerald, additional, Tischer, Johanna, additional, Scheid, Christoph, additional, Elmaagacli, Ahmet, additional, Neidlinger, Helga, additional, Flossdorf, Sarah, additional, Bornhäuser, Martin, additional, Bethge, Wolfgang, additional, Fleischhauer, Katharina, additional, Kröger, Nicolaus, additional, De Wreede, Liesbeth C., additional, and Christopeit, Maximilian, additional

Published
2023
Full Text
View/download PDF

41. S225: ALLOGENEIC STEM CELL TRANSPLANTATION FOR NK/T-CELL LYMPHOMA IN THE ERA OF ASPARAGINASE-BASED CHEMOTHERAPY: A RETROSPECTIVE ANALYSIS OF THE EBMT LYMPHOMA WORKING PARTY

Author

Berning, Philipp, primary, Schmitz, Norbert, additional, Ngoya, Maud, additional, Finel, Hevé, additional, Boumendil, Ariane, additional, Wang, Fengrong, additional, Huang, Xiaojun, additional, Hermine, Olivier, additional, Philippe, Laure, additional, Couronné, Lucile, additional, Jaccard, Arnaud, additional, Liu, Dai-Hong, additional, Wu, Depei, additional, Reinhardt, Christian, additional, Chalandon, Yves, additional, Wagner-Drouet, Eva, additional, Kwon, MI, additional, Zhang, XI, additional, Carpenter, Ben, additional, Yakoub-Agha, Ibrahim, additional, Wulf, Gerald, additional, Jimenez, Francisco Lopez, additional, Sanz, Jaime, additional, Wallet, Hélène Labussiere, additional, Shimoni, Avichai, additional, Dreger, Peter, additional, Sureda, Anna, additional, Kim, Won-Seog, additional, and Glass, Bertram, additional

Published
2023
Full Text
View/download PDF

43. Haploidentical Versus Matched Unrelated Donor Transplants Using Post-Transplantation Cyclophosphamide for Lymphomas

Author

Mussetti, Alberto, Kanate, Abraham S., Wang, Tao, He, Meilun, Hamadani, Mehdi, Finel, Hervé, Sr., Boumendil, Ariane, Sr., Glass, Bertram, Castagna, Luca, Dominietto, Alida, McGuirk, Joseph, Blaise, Didier, Gülbas, Zafer, Diez-Martin, Jose, Marsh, Steven G.E., Paczesny, Sophie, Gadalla, Shahinaz M., Dreger, Peter, Zhang, Mei-Jie, Spellman, Stephen R., Lee, Stephanie J., Bolon, Yung-Tsi, and Sureda, Anna

Published
2023
Full Text
View/download PDF

44. Gonadal Function after Busulfan Compared with Treosulfan in Children and Adolescents Undergoing Allogeneic Hematopoietic Stem Cell Transplant

Author

Faraci, Maura, Diesch, Tamara, Labopin, Myriam, Dalissier, Arnaud, Lankester, Arian, Gennery, Andrew, Sundin, Mikael, Uckan-Cetinkaya, Duygu, Bierings, Marc, Peters, Anke M.J., Garwer, Martina, Schulz, Ansgar, Michel, Gerard, Giorgiani, Giovanna, Gruhn, Bernd, Locatelli, Franco, Giardino, Stefano, Uyttebroeck, Anne, Rialland, Fanny, Itäla-Remes, Maija, Dreger, Peter, Shaw, Peter J., Bordon, Victoria, Schlegel, Paul G., Mellgren, Karin, Moraleda, Jose M., Patrick, Katharine, Schneider, Pascale, Jubert, Charlotte, Lawitschka, Anita, Salooja, Nina, Basak, Grzegorz W., Corbacioglu, Selim, Duarte, Rafael, and Bader, Peter

Published
2019
Full Text
View/download PDF

47. Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study

Author

Sengsayadeth, Salyka, Labopin, Myriam, Boumendil, Ariane, Finke, Jürgen, Ganser, Arnold, Stelljes, Matthias, Ehninger, Gerhard, Beelen, Dietrich, Niederwieser, Dietger, Blaise, Didier, Dreger, Peter, Mufti, Ghulam, Chevallier, Patrice, Mailhol, Audrey, Gatwood, Katie S., Gorin, Norbert, Esteve, Jordi, Ciceri, Fabio, Baron, Frederic, Schmid, Christoph, Giebel, Sebastian, Mohty, Mohamad, Savani, Bipin N., and Nagler, Arnon

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results